Gene expression profiling could be a useful method for identifying markers predictive of response to tumor necrosis factor (TNF) blockade in patients with rheumatoid arthritis (RA), according to ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for ...

EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, with a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo. The primary endpoint of the ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...